Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from Southwest Oncology Group trial 9346 (INT-0162)

Hussain, Maha; Tangen, Catherine; Higano, Celestia; Schelhammer, Paul; Faulkner, James; Crawford, E.; Wilding, George; Akdas, Atif; Small, Eric; Donnelly, Bryan; MacVicar, Gary; Raghavan, Derek

doi:10.1200/jco.2006.06.4246

Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from Southwest Oncology Group trial 9346 (INT-0162)

Atıf İçin Kopyala

Hussain M., Tangen C. M., Higano C., Schelhammer P. F., Faulkner J., Crawford E. D., ...Daha Fazla

JOURNAL OF CLINICAL ONCOLOGY, cilt.24, sa.24, ss.3984-3990, 2006 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 24 Sayı: 24
Basım Tarihi: 2006
Doi Numarası: 10.1200/jco.2006.06.4246
Dergi Adı: JOURNAL OF CLINICAL ONCOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.3984-3990
Marmara Üniversitesi Adresli: Hayır

Özet

Purpose To establish whether absolute prostate-specific antigen (PSA) value after androgen deprivation (AD) is prognostic in metastatic (D2) prostate cancer (PCa).